Pfizer fails to end lawsuit over Bextra, Celebrex safety
March 28 (Reuters) - Pfizer Inc has failed to persuade a federal judge to dismiss a shareholder lawsuit accusing the company of fraudulently misrepresenting the cardiovascular risks associated with its Bextra and Celebrex pain-relieving drugs.
While dismissing some of the shareholders' claims, U.S. District Judge Laura Taylor Swain in Manhattan said it was premature to dismiss the entire case.
Swain said a reasonable jury could find that Pfizer intended to mislead shareholders through its disclosures about the drugs' safety.
The plaintiffs are led by the Teachers' Retirement System of Louisiana, and a class was certified on July 5, 2012.
- Man called Bitcoin's father denies ties, leads LA car chase
- Ukraine standoff intensifies, Russia says sanctions will 'boomerang' |
- Florida mayor fights backyard gun ranges in 'Gunshine State'
- Apple loses bid for U.S. ban on Samsung smartphone sales
- 'Everything is fine', Pistorius told guard after shooting girlfriend |